Novartis’s Kymriah Receives EU Approval

 Novartis’s Kymriah Receives EU Approval

Novartis’s Kymriah Receives EU Approval

Shots:
  •  Post FDA approval in Aug 2017, Kymriah (tisagenlecleucel, formerly CTL019) receives EU approval for treatment of patients up to 25 years with (r/r), second or later stage in B-cell acute lymphoblastic leukemia (ALL) and with (r/r) diffuse large B-cell lymphoma (DLBCL)
  • The approval is based on two global trials JULIET and ELIANA results: JULIET(N=93): ORR 52%, CR 40%, 12% PR, mOS 11.7 mos; ELIANA (N=75): 81% achieved OR, 80% still in remission at 6 mos, 60% CR, 20% with iCR, mOS 19.1 mos
  •  With EU approval, Kymriah first-of-its-kind in CAR-T (chimeric antigen receptor T cell) therapy, is also designated as orphan medicinal product and one of the PRIME-designated therapies in enhancing QoL

Click here to read full press release/ article | Ref: Novartis | Image:  Novartis

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post